JP3481208B2 - ピリジン誘導体 - Google Patents
ピリジン誘導体Info
- Publication number
- JP3481208B2 JP3481208B2 JP2000502025A JP2000502025A JP3481208B2 JP 3481208 B2 JP3481208 B2 JP 3481208B2 JP 2000502025 A JP2000502025 A JP 2000502025A JP 2000502025 A JP2000502025 A JP 2000502025A JP 3481208 B2 JP3481208 B2 JP 3481208B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- phenyl
- vinyl
- pyridin
- pyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/26—Radicals substituted by halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/50—Ketonic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/52—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/53—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/57—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/30—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Description
疾病の処置のための、2−アリールアルケニル−、2−
ヘテロアリールアルケニル−、2−アリールアルキニル
−、2−ヘテロアリールアルキニル−、2−アリールア
ゾ−および2−ヘテロアリールアゾ−ピリジンの使用、
このような治療に使用する医薬組成物ならびに新規2−
アリールアルケニル−、2−ヘテロアリールアルケニル
−、2−アリールアルキニル−、2−ヘテロアリールア
ルキニル−、2−アリールアゾ−および2−ヘテロアリ
ールアゾ−ピリジンに関する。
−、2−ヘテロアリールアルケニル−、2−アリールア
ルキニル−、2−ヘテロアリールアルキニル−、2−ア
リールアゾ−および2−ヘテロアリールアゾ−ピリジン
(以後、本発明の薬剤)は、mGluRsの調節剤として有用で
ある。mGluRsの調節は、種々の方法で、とりわけ、二次
メッセンジャーアッセイまたは細胞内カルシウム濃度の
変化の測定のような結合アッセイおよび機能的アッセイ
で証明できる。例えば、hmGluR5aを発現する組換え細胞
系におけるリン酸イノシトールターンオーバーの測定
は、選択した本発明の薬剤で、約1nMから約50μMの
IC50値を示す。
有する。例えば、それらはヒト向代謝性(metabotropic)
グルタメートセレプター(mGluRs)で、顕著な、そして選
択的な調節、特に拮抗作用を示す。これは、インビトロ
で、例えば、組換えヒト向代謝性グルタメートレセプタ
ー、特にmGluR5のようなPLC−結合サブタイプで、例え
ば、L. P. Daggett et al. Neuropharm. Vol. 34, 871-
886 (1995), P. J. Flor et al., J. Neurochem. Vol.
67, 58-63 (1996)に従った細胞内Ca2+濃度のアゴニス
ト誘導上昇の阻害の測定、または、T. Knoepfel et al.
Eur. J. Pharmacol. Vol. 288, 389-392 (1994), L.
P. Daggett et al., Neuropharm. Vol. 67, 58-63 (199
6)およびその中の引用例に記載のような、どの程度リン
酸イノシトールターンオーバーのアゴニスト誘導上昇が
阻害されるかの測定を使用して測定できる。ヒトmGluR
サブタイプの単離および発現は、米国特許第5,521,297
号に記載されている。本発明の選択した薬剤は、キスカ
レート誘導リン酸イノシトールターンオーバーに関し
て、hmGluR5aを発現する組換え細胞で測定して、約1nM
から約50μMのIC50値を示す。
グナル伝達の不規則性に関する疾病、および全部または
一部mGluR5により介在される神経系疾患の処置に使用す
るための本発明の薬剤に関する。
性に関する疾病は、例えば、癲癇、脳虚血、特に急性虚
血、眼の虚血性疾患、一般的痙性ような筋肉痙性および
特に痙攣または疼痛である。
る神経系疾患は、例えば、パーキンソン病、老人性痴
呆、アルツハイマー病、ハンティングトン舞踏病、筋萎
縮性側索硬化症および多発性硬化症のような神経系の急
性、外傷性および慢性退行、精神分裂病および不安、鬱
病および疼痛のような精神病である。
伝達の不規則性に関する疾病、および全部または一部グ
ループI mGluRsにより介在される神経系疾病の処置に
も関連する。
ナル伝達の不規則性に関する疾病、および全部または一
部グループI mGluRsにより介在される神経系疾病の処
置のために設計された医薬組成物の製造における、本発
明の薬剤の使用に関する。
要とする温血生物に、治療的有効量の本発明の薬剤を投
与することを含む、全部または一部、グループI mGlu
Rs(好ましくはmGluR5)により介在される疾病の処置法に
も関する。
−アリールアルケニル−、2−ヘテロアリールアルケニ
ル−、2−アリールアルキニル−、2−ヘテロアリール
アルキニル−、2−アリールアゾ−および2−ヘテロア
リールアゾ−ピリジンおよびそれらの塩、ならびにそれ
らの製造法に関する。
新規2−アリールアルケニル−、2−ヘテロアリールア
ルケニル−、2−アリールアルキニル−、2−ヘテロア
リールアルキニル−、2−アリールアゾ−および2−ヘ
テロアリールアゾ−ピリジンおよびそれらの塩を、慣用
の薬学的賦形剤と共に含む医薬組成物にも関する。
アルキル低級アルキル−アミノ、ピペリジノ、カルボキ
シ、エステル化カルボキシ、アミド化カルボキシ、非置
換または低級アルキル−、低級アルコキシ−、ハロ−お
よび/またはトリフルオロメチル−置換N−低級−アル
キル−N−フェニルカルバモイル、低級アルコキシ、ハ
ロ−低級アルキルまたはハロ−低級アルコキシ、R2は
水素、低級アルキル、カルボキシ、エステル化カルボキ
シ、アミド化カルボキシ、ヒドロキシ−低級アルキル、
ヒドロキシ、低級アルコキシまたは低級アルカノイルオ
キシ、4−(4−フルオロ−ベンゾイル)−ピペリジン−
1−イル−カルボキシ、4−t.−ブチルオキシカルボニ
ル−ピペラジン−1−イル−カルボキシ、4−(4−ア
ジド−2−ヒドロキシベンゾイル)−ピペラジン−1−
イル−カルボキシまたは4−(4−アジド−2−ヒドロ
キシ−3−ヨード−ベンゾイル)−ピペラジン−1−イ
ル−カルボキシ、R3は水素、低級アルキル、カルボキ
シ、低級アルコキシ−カルボニル、低級アルキル−カル
バモイル、ヒドロキシ−低級アルキル、ジ−低級アルキ
ル−アミノメチル、モルホリノカルボニルまたは4−
(4−フルオロ−ベンゾイル)−ピペリジン−1−イル−
カルボキシ、R4は水素、低級アルキル、ヒドロキシ、
ヒドロキシ−低級アルキル、アミノ−低級アルキル、低
級アルキルアミノ−低級アルキル、ジ−低級アルキルア
ミノ−低級アルキル、非置換またはヒドロキシ−置換低
級アルキレンアミノ−低級アルキル、低級アルコキシ、
低級アルカノイルオキシ、アミノ−低級アルコキシ、低
級アルキルアミノ−低級アルコキシ、ジ−低級アルキル
アミノ−低級アルコキシ、フタルイミド−低級アルコキ
シ、非置換またはヒドロキシ−または2−オキソ−イミ
ダゾリジン−1−イル−置換低級アルキレンアミノ−低
級アルコキシ、カルボキシ、エステル化またはアミド化
カルボキシ、カルボキシ−低級−アルコキシまたはエス
テル化カルボキシ−低級−アルコキシ、Xは、ビシナル
不飽和炭素原子またはアゾ(−N=N−)基を介して結合
している所望によりハロ−置換されていてもよい低級ア
ルケニレンまたはアルキニレン基、そしてR5は、非置
換または、各々非置換または低級アルキル−低級アルコ
キシ−、ハロ−および/またはトリフルオロメチル−置
換であり得る低級アルキル、ハロ、ハロ−低級アルキ
ル、ハロ−低級アルコキシ、低級アルケニル、低級アル
キニル、非置換または低級アルキル−、低級アルコキシ
−、ハロ−および/またはトリフルオロメチル−置換フ
ェニル、非置換または低級アルキル−、低級アルコキシ
−、ハロ−および/またはトリフルオロメチル−置換フ
ェニル−低級アルキニル、ヒドロキシ、ヒドロキシ−低
級アルキル、低級アルカノイルオキシ−低級アルキル、
低級アルコキシ、低級アルケニルオキシ、低級アルキレ
ンジオキシ、低級アルカノイルオキシ、アミノ−、低級
アルキルアミノ−、低級アルカノイルアミノ−またはN
−低級アルキル−N−低級アルカノイルアミノ−低級ア
ルコキシ、非置換または低級アルキル−低級アルコキシ
−、ハロ−および/またはトリフルオロメチル−置換フ
ェノキシ、非置換または低級アルキル−低級アルコキシ
−、ハロ−および/またはトリフルオロメチル−置換フ
ェニル−低級アルコキシ、アシル、カルボキシ、エステ
ル化カルボキシ、アミド化カルボキシ、シアノ、カルボ
キシ−低級アルキルアミノ、エステル化カルボキシ−低
級アルキルアミノ、アミド化カルボキシ−低級アルキル
アミノ、ホスホノ−低級アルキルアミノ、エステル化ホ
スホノ−低級アルキルアミノ、ニトロ、アミノ、低級ア
ルキルアミノ、ジ−低級アルキルアミノ、アシルアミ
ノ、N−アシル−N−低級アルキルアミノ、フェニルア
ミノ、フェニル−低級アルキルアミノ、シクロアルキル
−低級アルキルアミノまたはヘテロアリール−低級アル
キルアミノから選択された1個またはそれ以上の置換基
で置換された芳香族または複素環式芳香族基である〕で
あって、通例の光親和性リガンドおよび通例の放射活性
マーカーであってよく、そのN−オキサイドおよび薬学
的に許容される塩を含む。
の形であり得、酸性基を有する式Iの化合物は、塩基と
塩を形成し得る。塩基性基および加えて少なくとも一つ
の酸性基を有する式Iの化合物は、内部塩も形成し得
る。また完全塩および部分塩、即ち、式Iの酸1モル当
り1、2または3、好ましくは2等量の塩基との塩、ま
たは式Iの塩基1モル当り1、2または3、好ましくは
1等量の酸との塩の両方を含む。
ない塩の使用もまた可能である。薬学的に許容される、
非毒性塩のみが治療的に使用され、従って、好ましい。
本明細書中のハロは、フッ素、塩素、臭素またはヨウ素
を意味する。Xがアルケニレン基であるとき、トランス
立体配置が好ましい。
して結合した所望によりハロ−置換されていてもよい
(C2-4)アルケニレンまたはアルキニレン基、R1が水
素、(C1-4)アルキル、(C1-4)アルコキシ、ヒドロキシ
(C1-4)アルキル、シアノ、エチニル、カルボキシ、(C
1-4)アルコキシカルボニル、ジ(C1-4)アルキルアミ
ノ、(C1-6)アルキルアミノカルボニル、トリフルオロ
メチルフェニルアミノカルボニル、R2が水素、ヒドロ
キシ、(C1-4)アルキル、ヒドロキシ(C1-4)アルキル、
(C1-4)アルコキシ、カルボキシ、(C2-5)アルカノイル
オキシ、(C1-4)アルコキシカルボニル、ジ(C1-4)アル
キルアミノ(C1-4)アルカノイル、ジ(C1-4)アルキルア
ミノメチル、4−(4−フルオロ−ベンゾイル)−ピペリ
ジン−1−イル−カルボキシ、4−t.−ブチルオキシカ
ルボニル−ピペラジン−1−イル−カルボキシ、4−
(4−アジド−2−ヒドロキシベンゾイル)−ピペラジン
−1−イル−カルボキシまたは4−(4−アジド−2−
ヒドロキシ−3−ヨード−ベンゾイル)−ピペラジン−
1−イル−カルボキシ、R3が水素、(C1-4)アルキル、
カルボキシ、(C1-4)アルコキシカルボニル、(C1-4)ア
ルキルカルバモイル、ヒドロキシ(C1-4)アルキル、ジ
(C1-4)アルキルアミノメチル、モルホリノカルボニル
または4−(4−フルオロ−ベンゾイル)−ピペリジン−
1−イル−カルボキシ、R4が水素、ヒドロキシ、(C
1-4)アルコキシ、カルボキシ、(C2-5)アルカノイルオ
キシ、(C1-4)アルコキシカルボニル、アミノ(C1-4)ア
ルコキシ、ジ(C1-4)アルキルアミノ(C1-4)アルコキ
シ、ジ(C1-4)アルキルアミノ(C1-4)アルキル、カルボ
キシ(C1-4)アルキルカルボニル、(C1-4)アルコキシカ
ルボニル(C1-4)アルコキシ、ヒドロキシ(C1-4)アルキ
ル、ジ(C1-4)アルキルアミノ(C1-4)アルコキシ、m−
ヒドロキシ−p−アジドフェニルカルボニルアミノ(C
1-4)アルコキシ、そしてR5が式
キシ、ハロゲン、ニトロ、シアノ、カルボキシ、
(C1-4)アルキル、(C1-4)アルコキシ、ヒドロキシ(C
1-4)アルキル、(C1-4)アルコキシカルボニル、(C2-7)
アルカノイル、(C2-5)アルカノイルオキシ、(C2-5)ア
ルカノイルオキシ(C1-4)アルキル、トリフルオロメチ
ル、トリフルオロメトキシ、トリメチルシリルエチニ
ル、(C2-5)アルキニル、アミノ、アジド、アミノ(C
1-4)アルコキシ、(C2-5)アルカノイルアミノ(C1-4)ア
ルコキシ、(C1-4)アルキルアミノ(C1-4)アルコキシ、
ジ(C1-4)アルキルアミノ(C1-4)アルコキシ、(C1-4)
アルキルアミノ、ジ(C1-4)アルキルアミノ、モノハロ
ベンジルアミノ、チエニルメチルアミノ、チエニルカル
ボニルアミノ、トリフルオロメチルフェニルアミノカル
ボニル、テトラゾリル、(C2-5)アルカノイルアミノ、
ベンジルカルボニルアミノ、(C1-4)アルキルアミノカ
ルボニルアミノ、(C1-4)アルコキシカルボニル−アミ
ノカルボニルアミノまたは(C1-4)アルキルスルホニ
ル、Rcは水素、フッ素、塩素、臭素、ヒドロキシ、(C
1-4)アルキル、(C2-5)アルカノイルオキシ、(C1-4)ア
ルコキシまたはシアノ、そしてRdは水素、ハロゲンま
たは(C1-4)アルキル〕の基である式Iの化合物が好ま
しい。
上記で定義の意味、そしてR1が水素、(C1-4)アルキ
ル、(C1-4)アルコキシ、シアノ、エチニルまたはジ(C
1-4)アルキルアミノ、R2が水素、ヒドロキシ、カルボ
キシ、(C1-4)アルコキシカルボニル、ジ(C1-4)アルキ
ルアミノメチル、4−(4−フルオロ−ベンゾイル)−ピ
ペリジン−1−イル−カルボキシ、4−t.−ブチルオキ
シカルボニル−ピペラジン−1−イル−カルボキシ、4
−(4−アジド−2−ヒドロキシベンゾイル)−ピペラジ
ン−1−イル−カルボキシまたは4−(4−アジド−2
−ヒドロキシ−3−ヨード−ベンゾイル)−ピペラジン
−1−イル−カルボキシ、R3が上記で定義の意味、R4
が水素、ヒドロキシ、カルボキシ、(C2-5)アルカノイ
ルオキシ、(C1-4)アルコキシカルボニル、アミノ(C
1-4)アルコキシ、ジ(C1-4)アルキルアミノ(C1-4)アル
コキシ、ジ(C1-4)アルキルアミノ(C1-4)アルキルまた
はヒドロキシ(C1-4)アルキル、そしてR5が式
ニトロ、シアノ、(C1-4)アルキル、(C1.4)アルコキ
シ、トリフルオロメチル、トリフルオロメトキシまたは
(C2-5)アルキニル、そしてRcおよびRdが上記で定義
の意味〕の基であるものである。
載の化合物を含む。上記疾病の処置における本発明の薬
剤の有用性は、下記のものを含む標準試験の範囲で確認
される:約10から100mg/kg i.p.またはp.o.の量
で、15分から8時間の処置時間で、本発明の薬剤は電
気ショック誘導痙攣モデルで抗痙攣活性を示す[参照、
E.A. Swinyard, J. Pharm. Assoc. Scient. Ed. 38, 20
1 (1949)およびJ. Pharmacol. Exptl. Therap. 106, 31
9 (1952)]。
明の薬剤は、フロイント完全アジュバント(FCA)誘導痛
覚過敏の回復を示す[参照、J. Donnerer et al., Neuro
science 49, 693-698 (1992) and C.J. Woolf, Neurosc
ience 62, 327-331 (1994)]。
量は、もちろん、例えば、用いる化合物、宿主、投与形
態および処置する状態の性質および重症度に依存して変
化する。しかし、一般に、約0.5から約100mg/kg
動物体重の一日量で、動物において十分な結果が示され
る。大型哺乳類、例えばヒトにおいて、示される一日量
は、約5から1500mg、好ましくは約10から約10
00mgの化合物であり、簡便には一日4回までの分割量
で、または持続放出形で投与する。
−[2−trans−(3,5−ジクロロフェニル)−ビニル]−
6−メチル−ピリジン−3−イルオキシ}−プロピル)−
ジメチルアミン(A)、2−メチル−6−スチリル−ピリ
ジン(B)、2−(3−フルオロ−フェニルエチニル)−6
−メチル−ピリジン(C)および2−(4−エトキシ−3
−トリフルオロメチル−フェニルエチニル)−6−メチ
ル−ピリジン(D)を含む。例えば、上記電気ショック誘
導痙攣モデルにおいて、化合物AおよびBは、各々30
および35mg/kg i.p.のED50(前処置時間:各々4時間
および15分)を、およびFCA誘導痛覚過敏モデルにおい
て、化合物CおよびDは、各々4.2および19mg/kg
p.o.のED50を示す(後処置時間:3時間)。
アリールアルケニル−、2−ヘテロアリールアルケニル
−、2−アリールアルキニル−、2−ヘテロアリールア
ルキニル−、2−アリールアゾ−および2−ヘテロアリ
ールアゾ−ピリジンおよびその塩を含み、以後“本発明
の化合物”と称する。
R5が上記で定義の意味である上記の式Iの化合物およ
びその塩を含むが、但し、R3が水素のとき、 a)R1、R2およびR4が水素である式Iの化合物におい
て、XがエテニレンのときR5はフェニル、モノハロフ
ェニル、2,4−および3,4−ジクロロフェニル、3−
および4−トリフルオロメチルフェニル、メチルフェニ
ル、3,4−および2,5−ジメチルフェニル、4−イソ
プロピルフェニル、3,5−ジ−tert.−ブチルフェニ
ル、メトキシフェニル、3,4−ジメトキシフェニル、
2,4,5−および3,4,5−トリメトキシフェニル、ヒ
ドロキシフェニル、3,5−ジヒドロキシフェニル、4
−ヒドロキシ−3,5−ジメチル−フェニル、3−ヒド
ロキシ−4−メトキシ−および4−ヒドロキシ−3−メ
トキシ−フェニル、4−ヒドロキシ−(3−メチル−5
−tert.−ブチル−、2−および4−アセチルアミノフ
ェニル、3,5−ジイソプロピル−および3,5−ジ−te
rt.−ブチル)フェニル、4−カルボキシ−および4−エ
トキシカルボニルフェニル、4−シアノフェニル、3−
メトキシカルボニルフェニル、3−カルボキシ−5−メ
トキシ−フェニル、2−ピリジニル、5−クロロ−2−
ピリジニルおよび6−メチル−2−ピリジニルではな
い、またはXが2位でR5に結合した1,2−プロピレン
であるとき、R5はフェニル、4−メチルフェニル、4
−メトキシフェニル、4−ブロモフェニルおよび2−お
よび4−クロロフェニルではない、またはXが1位でR
5に結合した1,2−プロピレンであるとき、R5はフェ
ニル、2−および4−クロロフェニルおよび3−メトキ
シフェニルではない、またはXが2位でR5に結合した
2,3−ブテ−2−エニレンまたは1,2−ブテ−1−エ
ニレンであるとき、R5は4−メトキシフェニルではな
い、またはXが3位でR5に結合した2,3−ペンテ−2
−エニレンであるとき、R5は4−メトキシフェニルお
よび4−イソプロピルフェニルではない、またはXが
3,4−ヘキセ−3−エニレンであるとき、R5はフェニ
ル、4−メチルフェニル、メトキシフェニルおよび4−
ヒドロキシフェニルではない;
素である式Iの化合物において、Xがエテニレンである
とき、R5はフェニル、3−メチルフェニル、2−メト
キシフェニル、2−クロロフェニル、4−シアノフェニ
ル、2−ピリジニルおよび6−メチル−2−ピリジニル
ではない; c)R1およびR2が水素ならびにR4がカルボキシである
式Iの化合物において、Xがエテニレンであるとき、R
5はフェニル、3−メチルフェニル、4−メトキシフェ
ニルおよび4−ブロモフェニルではない; d)R1およびR2が水素ならびにR4がメチルである式I
の化合物において、Xがエテニレンのとき、R5はフェ
ニル、3−メトキシ−、4−メトキシ−および3,4−
ジメトキシフェニル、2−クロロ−および2,4−ジク
ロロフェニルおよび6−メチル−ピリド−2−イルでは
ない、またはXが2位でR5に結合した1,2−プロペ−
1−エニレンのとき、R5はフェニルではない;
ジメチルアミノエトキシカルボニルまたは3−ジメチル
アミノプロピルオキシカルボニルである式Iの化合物に
おいて、Xがエテニレンであるとき、R5は4−メトキ
シフェニルではない; f)R1およびR2が水素ならびにR4が2−ジメトキシエ
トキシである式Iの化合物において、Xがエテニレンで
あるとき、R5はフェニル、4−メチルフェニルおよび
4−メトキシカルボニルフェニルではない; g)R1およびR2が水素ならびにR4がヒドロキシまたは
エトキシカルボニルであるとき、またはR1およびR2が
水素およびR4がヒドロキシであるとき、またはR1がメ
チル、R2が水素およびR4がメトキシであるとき、また
はR1がブテ−1−エニル、R2が水素およびR4が水
素、またはR1が水素およびR4が2−ジメトキシエトキ
シであり、Xがいずれの場合もエテニレンであるとき、
R5はフェニルではない、
であるとき、 a')R1、R2およびR4が水素であるとき、R5はフェニ
ル、2−および4−ニトロフェニル、4−アミノフェニ
ル、4−クロロフェニル、4−メチルフェニル、4−メ
トキシフェニル、4−エトキシカルボニルフェニル、5
−ホルミル−2−メトキシ−フェニル、5−カルボキシ
−2−メチオ(methyo)−フェニルおよびピリジルではな
い; b')R2およびR4が水素である式Iの化合物において、
R1がメチルであるとき、R5はフェニル、3−メチルフ
ェニル、6−メチルピリジン−2−イルおよび2−メト
キシフェニルではない、R1がブロモであるとき、R5は
6−ブロモピリジン−2−イルではない、そしてR1が
ヘキシルオキシであるとき、R5は6−ヘキシルオキシ
ピリジン−2−イルではない;
物において、R2がメチルであるとき、R5はフェニル、
4−アミノフェニルおよび4−プロピルフェニルではな
い、R2がエチルであるとき、R5はフェニル、4−シア
ノフェニルおよび4−ペンチルフェニルではない、R2
がブチルであるとき、R5は3−シアノ−4−エトキシ
−フェニルおよび3−ブロモ−4−メトキシ−フェニル
ではない、R2がペンチルであるとき、R5は4−メトキ
シフェニルおよび4−ブチルオキシフェニルではない、
R2がカルボキシであるとき、R5は4−ter.−ブチルフ
ェニル、3−tert.−ブチル−4−ヒドロキシ−フェニ
ル、4−tert.−ブチル−3−ヒドロキシ−フェニルお
よび4−ヘキシルオキシフェニルではない、R2がメト
キシカルボニルまたはメチルカルバモイルであるとき、
R5はフェニルではない、R2がエトキシカルボニルであ
るとき、R4は3−tert.−ブチルフェニル、3−tert.
−ブチル−4−ヒドロキシ−フェニルおよび4−(4−
メチルペンチル)フェニルではない、そしてR2が2−メ
チルブチルオキシカルボニルであるとき、R5は4−ペ
ンチルオキシフェニルではない; d')R1およびR2が水素である式Iの化合物において、
R4がヒドロキシ、メチル、エチル、カルボキシ、メト
キシカルボニルまたはカルバモイルであるとき、R5は
フェニルではない。
として上記であるものである。本発明の化合物は、既知
の式Iの化合物の合成と同様にして製造できる。
えば a)式II
およびY2の一方は低級アルカノイルおよび他方は低級
アルキルまたはトリアリールホスホロアニリデンメチル
であるか、またはY1およびY2の一方が反応性エステル
化ヒドロキシ基および他方がY3−X−であり、Y3は水
素または金属基である、そしてR1、R2、R3、R4およ
びR5は前記の意味を有し、官能基R1、R2、R3および
R4ならびにR5の官能性置換基は一時的に保護され得
る)、または b)式IV
基、R1、R2、R3、R4、XおよびR5は前記の意味を
有し、官能基R1、R2、R3およびR4ならびにR5の官
能性置換基は一時的に保護され得る)、一時的保護基を
除去する、そして、所望により、上記方法で得られる式
Iの化合物を異なる式Iの化合物に変換し、得られ得る
異性体の混合物を個々の異性体に分割しおよび/または
上記方法で得られる少なくとも一つの塩形成基を有する
式Iの化合物を式に変換し、または上記方法で得られる
塩を遊離化合物または別の塩に変換することを含む方法
で製造できる。
くはY1基は、例えば、ホルミル、アセチルまたはプロ
ピオニルのようなC1−C3アルカノイル基、特にホルミ
ルである。低級アルキル基Y1またはより好ましくはY2
は、例えば、メチル、エチルまたはプロピルのようなC
1−C3アルキル基、特にメチルである。トリアリールホ
スホロアニリデンメチルY2またはより好ましくはY
1は、例えば、トリフェニルホスホロアニリデンメチル
である。
ドロキシ基、他方が式Y3−X−(式中、Y3は水素)であ
るとき、縮合は、このましくはへックカップリング法に
従って、例えば、パラジウムまたは、トリアリールホス
フィンの存在下、PdII塩のような銅または銅触媒または
貴金属/ホスフィン触媒の存在下、例えば酢酸パラジウ
ム、およびトリフェニルホスフィン、またはビス−トリ
フェニルホスフィン−パラジウムジクロライドの存在
下、好ましくはトリ−低級アルキルアミン、例えば、ト
リメチルアミンの存在下、有利にはCuI−Iの存在下、
N,N−ジ−低級アルキル−アルカノン酸アミド、例え
ば、ジメチルホルムアミド、ジ−低級アルキルスルホキ
シド、例えば、ジメチルスルホキシド、またはジオキサ
ンのような極性有機溶媒中、約15℃から約120℃の
温度、好ましくは沸騰しながら行う。
ドロキシ基および他方が式Y3−X−(式中、Y3はハロ
−マグネシウム基のような金属基)であるとき、反応は
好ましくは金属中間体が好ましくはその場で形成される
グリニャール法で行う。
よび他方が低級アルキルであるとき、式IIとIIIの化合
物の分子間縮合は、好ましくはショーおよびワグスタッ
フ法またはその多くの変形の一つに従って行う。
よび他方がトリアリールホスホロアニリデンメチルであ
るとき、縮合は好ましくは、既知のヴィティヒオレフィ
ン−ビルディング法に従って、好ましくはホスホロアニ
リデン要素を、対応するトリアリールホスホニウムハラ
イドからその場で形成させ、例えば、後者を、ナトリウ
ムハイドライドのようなアルカリ金属ハイドライドのよ
うな金属塩基、またはブチルリチウムのような低級アル
キル金属化合物のような金属−有機塩基、またはアルカ
リ金属アルカノラート、例えば、3級ブトキシドカリウ
ムと、好ましくは、芳香族またはアリール脂肪族炭化水
素、例えば、ベンゼンまたはトルエンのような不活性有
機溶媒中、約−10℃から約39℃、好ましくは最初に
0°から10℃で、次いで環境温度で行う。
機酸でエステル化したヒドロキシ基のようなエステル化
ヒドロキシ基、例えば無機酸でエステル化された低級ア
ルカノイルオキシまたはヒドロキシ基、例えば、ハロ
基、もしくはトリ低級アルキルアミノ基のような3級ア
ミノ基、例えば、トリメチルアミノ、もしくはピロリジ
ノ、ピペリジノ、モルホリノまたはチオモルホリノのよ
うな低級アルケンアミノ、低級アザアルキレンアミノ、
低級オキシアルキレンアミノまたは低級チアアルキレン
アミノ基、または対応する4級アンモニウム基である。
護基それ自体およびそれらの除去の反応は、例えば、標
準著書に記載されている。H−Y4の式Iの化合物IVか
らの除去は通例の方法で行うことができる。従って、水
または低級アルカノン酸を、例えば、トルエン中、有利
には弱い塩基性条件下、共沸蒸留により除去し得る。水
素化ハライドは、好ましくは溶媒または共溶媒としての
対応する低級アルカノール中、アルカリ金属アルカノラ
ートとの反応のような塩基性条件下、またはトリ−低級
アルキルアミンのような3級アミンの存在下の加熱によ
り除去し得る。
る。新規出発物質は既知の出発物質の製造法と同様の方
法で得ることができる。本方法で得ることができる式I
の化合物は、異なる式Iの化合物に、慣用法で変換で
き、例えば遊離カルボキシ基をエステル化またはアミド
化し得、エステル化またはアミド化カルボキシ基を遊離
カルボキシ基に変換し得、エステル化カルボキシ基を非
置換または置換カルバモイル基に変換でき、遊離アミノ
基をアシル化またはアルキル化でき、そしてヒドロキシ
をアシル化できる。
との反応のような慣用法で酸化でき、対応するピリジン
−N−オキサイド誘導体を得る。式Iの化合物の塩は、
それ自体既知の方法で、例えば、塩基または酸との処理
により、遊離化合物に変換できる。
る塩に変換できる。その塩を含む式Iの化合物は、水和
物の形でも得られ得、また結晶化に使用した溶媒を含み
得る。
関係の結果、上記および下記での遊離化合物およびそれ
らの塩の言及は、遊離化合物ならびに対応する塩を含む
と理解されるべきである。
の立体配置は、選択的に反転できる。アミノまたはヒド
ロキシのような求核置換基を担持する不斉炭素原子の立
体配置は、所望により結合した求核置換基の安定なヌク
レオフーガル脱離基への変換および本来の置換基を挿入
する試薬との反応後、セカンドオーダー求核置換により
反転でき、またはヒドロキシ基を有する炭素原子での立
体配置は、欧州特許出願EP-A-0 236 734と同様に、酸化
および還元により反転できる。
医薬組成物にも関する。本発明の薬学的に許容される化
合物は、例えば、有効量の活性成分を、有意な量の無機
または有機、固体または液体の薬学的に許容される担体
と共に、または混合物として含む医薬組成物の製造に使
用し得る。
活性成分を、単独でまたは有意な量の薬学的に許容され
る担体と共に含む、温血動物(ヒトおよび動物)への経
鼻、直腸または経口のような経腸、または筋肉内または
静脈内のような非経腸投与用組成物である。活性成分の
量は、温血動物種の種類、体重、年齢および個々の状
態、個々の薬物動態データ、処置する疾病および投与形
態に依存する。
しくは約20%から約90%の活性成分を含む、本発明
の医薬組成物は、例えば、アンプル、バイアル、坐薬、
糖衣錠、錠剤またはカプセルのような単位投与形であり
得る。本発明の医薬組成物は、それ自体既知の方法で、
例えば、慣用の溶解、凍結乾燥、混合、粒状化または糖
菓剤製造の手段により製剤する。
ヒトへ投与する量は、特に、グルタミン酸作動性シグナ
ル伝達の不規則性によりもたらされるまたは関連する疾
病に有効な量で、一人当り一日当り約3mgから約3g、
好ましくは約10mgから約1g、例えば約20mgから5
00mgで、好ましくは、例えば、同じ大きさであり得る
1から4回の一投与量に分ける。通常、子供は成人の量
の約半分を投与される。各個体に必要な投与量は、例え
ば、活性成分の血清濃度の測定により追跡し、最適レベ
ルに調節し得る。
ために提供する;温度は摂氏、圧力はmbarで示す。
ベンゾニトリル 2,6−ジメチルピリジン(4.2ml、36.28mMol)、
3−シアノベンズアルデヒド(4.95g、37.74mMo
l)の無水酢酸(6.85ml)溶液を、16時間還流下で加
熱する。無水酢酸を、次いで真空で蒸発させ、残渣をカ
ラムクロマトグラフィー(シリカゲル400g)で精製す
る。カラムを最初にトルエン(400ml)、次いでトルエ
ン/酢酸エチル95:5で溶出する。所望の化合物を含
むフラクションを合わせ、真空で蒸発させる。固体残渣
を塩化メチレン/ヘキサンから再結晶し、3.18gの白
色結晶を単離する。(融点:91−92°)。
−ベンゾニトリル 2,6−ジメチルピリジン(5.8ml、50mMol)、2−シ
アノベンズアルデヒド(6.81g、52mMol)の無水酢酸
(9.5ml)溶液を、16時間還流下で加熱する。無水酢
酸を、次いで真空で蒸発させ、残渣をカラムクロマトグ
ラフィー(シリカゲル400g)で精製する。カラムを最
初にトルエン(400ml)、次いでトルエン/酢酸エチル
95:5で溶出する。所望の化合物を含むフラクション
を合わせ、真空で蒸発させる。固体を塩化メチレン/ジ
イソプロピルエーテルから単離し、白色結晶を単離す
る。(融点:113−114°)。
−ピリジン 2,6−ジメチルピリジン(5.8ml、50mMol)、ピリジ
ン−4−カルボアルデヒド(4.9ml、52mMol)の無水
酢酸(9.5ml)溶液を、16時間還流下で加熱する。無
水酢酸を、次いで真空で蒸発させ、残渣をカラムクロマ
トグラフィー(シリカゲル900g)で精製する。カラム
を、最初にトルエン/アセトン4:1(5L)、次いでト
ルエン/アセトン3:1(5L)および最後にトルエン/
アセトン2:1(15L)で溶出する。所望の化合物を含
むフラクションを合わせ、真空で蒸発させる。固体残渣
を塩化メチレン/ジイソプロピルエーテルから再結晶
し、0.956gの白色結晶を単離する。(融点:72−
73℃)。
−ピリジン 2,6−ジメチルピリジン(5.8ml、50mMol)、ピリジ
ン−3−カルボアルデヒド(4.9ml、52mMol)の無水
酢酸(9.5ml)溶液を、10時間還流下で加熱する。無
水酢酸を、次いで真空で蒸発させ、残渣をカラムクロマ
トグラフィー(シリカゲル900g)で精製する。カラム
を、最初にトルエン/アセトン9:1(7L)、次いでト
ルエン/アセトン4:1(5L)および最後にトルエン/
アセトン2:1(5L)で溶出する。所望の化合物を含む
フラクションを合わせ、真空で蒸発させる。固体残渣を
塩化メチレン/ジイソプロピルエーテルから再結晶し、
4.28gの無色油状物を得、それは6−8℃で放置して
固化する。
−ピリジン 1.2g(2.8mMol)の2−[1,2−ジブロモ−2−(3−
ブロモフェニル)−エチル]−6−メチル−ピリジンを1
0mlのエタノールに溶解する。0.9g(16.1mMol)の
水酸化カリウム(粉末)を添加し、得られる懸濁液を4時
間、還流下加熱する。次いで、懸濁液を室温に冷却し、
100mlの食塩水に注ぎ、3回、各30mlのt−ブチル
メチルエーテルで抽出する。合わせた有機相を30mlの
食塩水で洗浄し、硫酸ナトリウムで乾燥させ、濾過して
真空で蒸発させる。0.720gの標題化合物を、放置に
より結晶化する無色油状物として得る;融点60−61
°。
チル−ピリジン 24ml(200mMol)の2,6−ジメチルピリジンおよび
25.6ml(207mMol)の3−ブロモベンズアルデヒド
の38mlの無水酢酸溶液を、7.5時間加熱還流する。
次いで、無水酢酸を真空で蒸発させ、残渣を500mlの
4N塩酸に溶解し、2回、各200mlのヘキサンで抽出
する。次いで、水相を、4回、各300mlのtert.−ブ
チルメチルエーテルで抽出する。合わせた有機相を、2
回、各300mlのNaHCO3の飽和水溶液で、次いで、
1回、300mlの食塩水(300ml)で洗浄し、硫酸ナト
リウムで乾燥させ、濾過し、真空で蒸発させて、4.2g
の標題化合物を融点58−59°の無色結晶として得
る。
モフェニル)−エチル]−6−メチル−ピリジン 1g(3.6mMol)の2−(3−ブロモ−フェニルエチニル)
−6−メチル−ピリジンを、5mlの四塩化炭素に溶解
し、溶液を55−60°に加熱する。0.23ml(4.4m
Mol)の臭素Br2の1mlの四塩化炭素溶液を滴下する。
反応混合物を55−60°に30分維持し、次いで室温
に冷却する。得られる沈殿を濾過して回収し、真空で乾
燥させる。1.3gの、融点164−166の黄色結晶の
形の標題化合物が単離される。
ベンゾニトリル 1g(8.54mMol)2−エチニル−6−メチル−ピリジン
(D. E. Ames et al.,Synthesis, 1981, p. 364-5と同様
に製造)、2.3g(12.8mMol)3−ブロモ−ベンゾニト
リル、0.47g(0.7mMol)ビス−(トリフェニルホスフ
ィン)−パラジウム−II−クロライド、80mg(0.41m
Mol)ヨウ化第一銅および1.53ml(15mMol)トリエチ
ルアミンの混合物の10mlジメチルホルムアミド溶液
を、3時間90℃で撹拌する。反応混合物を環境温度に
冷却し、水に注ぎ、ジクロロメタンで抽出する。有機層
を硫酸ナトリウムで乾燥させ、濾過し、蒸発乾固して、
残渣をシリカゲルで、溶出液としてのヘキサン/酢酸エ
チル(4:1)でクロマトグラフィーすることにより精製
する。得られた生産物のヘキサンからの結晶化により、
0.53g(28.4%)の標題化合物が茶色結晶として得
られる、融点120−3℃。
がアルキニレンであるとき)に類似の方法により、以下
の式Iの化合物を製造できる:
Claims (5)
- 【請求項1】 遊離形または薬学的に許容される塩形
の、式I 【化1】 〔式中、 Xは、エチニレン、 R1は(C1−4)アルキル、(C1−4)アルコキシ、シ
アノ、エチニルまたはジ(C1−4)アルキルアミノ、 R2は水素、ヒドロキシ、カルボキシ、(C1−4)アル
コキシカルボニル、ジ(C1−4)アルキルアミノメチ
ル、4−(4−フルオロ−ベンゾイル)−ピペリジン−1
−イル−カルボキシ、4−t.−ブチルオキシカルボニ
ル−ピペラジン−1−イル−カルボキシ、4−(4−ア
ジド−2−ヒドロキシベンゾイル)−ピペラジン−1−
イル−カルボキシまたは4−(4−アジド−2−ヒドロ
キシ−3−ヨード−ベンゾイル)−ピペラジン−1−カ
ルボキシ、 R3は水素、(C1−4)アルキル、カルボキシ、(C
1−4)アルコキシカルボニル、(C1−4)アルキルカ
ルバモイル、ヒドロキシ(C1−4)アルキル、ジ(C
1−4)アルキルアミノメチル、モルホリノカルボニル
または4−(4−フルオロ−ベンゾイル)−ピペリジン−
1−イル−カルボキシ、 R4は水素、ヒドロキシ、カルボキシ、(C2−5)アル
カノイルオキシ、(C1−4)アルコキシカルボニル、ア
ミノ(C1−4)アルコキシ、ジ(C1−4)アルキルアミ
ノ(C1−4)アルコキシ、ジ(C1−4)アルキルアミノ
(C1−4)アルキルまたはヒドロキシ(C1−4)アルキ
ル、そして R5は、式 【化2】 (式中、RaおよびRbは各々独立して水素、ハロゲン、
ニトロ、シアノ、(C1-4)アルキル、(C1-4)アルコキ
シ、トリフルオロメチル、トリフルオロメトキシまたは
(C2-5)アルキニル、 Rcは水素、フッ素、塩素、臭素、ヒドロキシ、(C1-4)
アルキル、(C2-5)アルカノイルオキシ、(C1-4)アルコ
キシまたはシアノ、そして Rdは水素、ハロゲンまたは(C1-4)アルキルである) の基であるが、 但し、R2、R3およびR4が水素である化合物におい
て、R1がメチルである場合、R5はフェニル、3−メ
チルフェニル、6−メチルピリジン−2−イルおよび3
−メトキシフェニルではない〕 の化合物。 - 【請求項2】 R5が所望により置換されていてもよい
フェニルではない、遊離形または薬学的に許容される塩
形の、請求項1記載の化合物。 - 【請求項3】 R5が所望により置換されていてもよい
ピリジン−3−イルである、遊離形または薬学的に許容
される塩形の、請求項2記載の化合物。 - 【請求項4】 遊離形または薬学的に許容される塩形
の、2−[2−(ピリジン−3−イル)エチニル]−6−メ
チル−ピリジンである、請求項1記載の化合物。 - 【請求項5】 薬学的賦形剤と共に、遊離形または薬学
的に許容される塩形の、請求項1〜4のいずれかに記載
の化合物を薬学的有効成分として含む、グルタミン酸作
動性シグナル伝達の不規則性に関連する疾病、または全
部または部分的にmGluR5により仲介される神経系疾患の
処置に使用するための医薬組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89068997A | 1997-07-11 | 1997-07-11 | |
US89169197A | 1997-07-11 | 1997-07-11 | |
US08/890,689 | 1997-07-11 | ||
US08/891,691 | 1997-07-11 | ||
PCT/EP1998/004266 WO1999002497A2 (en) | 1997-07-11 | 1998-07-09 | Pyridine derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001509504A JP2001509504A (ja) | 2001-07-24 |
JP3481208B2 true JP3481208B2 (ja) | 2003-12-22 |
Family
ID=27128958
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000502025A Expired - Fee Related JP3481208B2 (ja) | 1997-07-11 | 1998-07-09 | ピリジン誘導体 |
Country Status (26)
Country | Link |
---|---|
US (1) | US6656957B1 (ja) |
EP (1) | EP0998459B1 (ja) |
JP (1) | JP3481208B2 (ja) |
KR (1) | KR20010021712A (ja) |
CN (1) | CN1203060C (ja) |
AR (1) | AR016314A1 (ja) |
AT (1) | ATE393145T1 (ja) |
AU (1) | AU738973B2 (ja) |
BR (1) | BR9811685A (ja) |
CA (1) | CA2295678C (ja) |
DE (1) | DE69839398T2 (ja) |
ES (1) | ES2308811T3 (ja) |
HU (1) | HUP0004225A3 (ja) |
ID (1) | ID23889A (ja) |
IL (1) | IL133904A0 (ja) |
MY (1) | MY119800A (ja) |
NO (1) | NO20000124L (ja) |
NZ (1) | NZ502210A (ja) |
PE (1) | PE97799A1 (ja) |
PL (1) | PL343865A1 (ja) |
PT (1) | PT998459E (ja) |
RU (1) | RU2203889C2 (ja) |
SK (1) | SK232000A3 (ja) |
TR (1) | TR200000059T2 (ja) |
TW (1) | TW544448B (ja) |
WO (1) | WO1999002497A2 (ja) |
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ID29095A (id) * | 1998-10-02 | 2001-07-26 | Novartis Ag Cs | Antagonis mglur5 untuk pengobatan rasa sakit dan kegelisahan |
WO2000064430A1 (fr) * | 1999-04-23 | 2000-11-02 | Sumitomo Pharmaceuticals Co., Ltd. | Inhibiteurs de l'apoptose |
FR2793245B1 (fr) * | 1999-05-05 | 2002-10-11 | Adir | Nouveaux composes pyridiniques ou piperidiniques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US6660753B2 (en) | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
US6774138B2 (en) | 1999-08-31 | 2004-08-10 | Merck & Co., Inc. | Thiazolyl(pyridyl)ethyne compounds |
CA2383524C (en) * | 1999-08-31 | 2010-09-28 | Merck & Co., Inc. | Thiazolyl alkynyl compounds and methods of use thereof |
GB0005700D0 (en) * | 2000-03-09 | 2000-05-03 | Glaxo Group Ltd | Therapy |
US7205297B2 (en) | 2000-07-24 | 2007-04-17 | Krenitsky Pharmaceuticals, Inc. | Substituted 5-alkynyl pyrimidines having neurotrophic activity |
CN1257894C (zh) | 2000-12-04 | 2006-05-31 | 弗·哈夫曼-拉罗切有限公司 | 作为谷氨酸受体拮抗剂的苯基乙烯基或苯基乙炔基衍生物 |
GB0103045D0 (en) * | 2001-02-07 | 2001-03-21 | Novartis Ag | Organic Compounds |
NZ527691A (en) * | 2001-02-21 | 2007-01-26 | Nps Pharma Inc | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
US8124625B2 (en) | 2001-09-14 | 2012-02-28 | Shionogi & Co., Ltd. | Method of enhancing the expression of apolipoprotein AI using olefin derivatives |
CA2462442A1 (en) * | 2001-10-12 | 2003-04-24 | Warner-Lambert Company Llc | Alkyne matrix metalloproteinase inhibitors |
US6951875B2 (en) * | 2001-10-29 | 2005-10-04 | Hoffmann-La Roche Inc. | Conjugated aromatic compounds with a pyridine substituent |
GB0128996D0 (en) | 2001-12-04 | 2002-01-23 | Novartis Ag | Organic compounds |
WO2003093236A1 (en) * | 2002-05-02 | 2003-11-13 | Euro-Celtique, S.A. | 1-(pyrid-2-yl)-piperazine compounds as metabotropic glutamate receptor inhibitor |
AU2003253149A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 3,4-dihydroquinolin-2-one, 5,6-fused oxazin-3-one, and 5,6-fused thiazin-3-one derivatives as matrix metalloproteinase inhibitors |
EP1539749A4 (en) * | 2002-09-13 | 2007-06-13 | Merck & Co Inc | BY CONDENSED HETEROBICYCLOGRUPPEN SUBSTITUTED PHENYL COMPOUNDS AS METOBOTROPE GLUTAMATE-5 MODULATORS |
CA2503245A1 (en) * | 2002-10-24 | 2004-05-06 | Merck & Co., Inc. | Alkyne derivatives as tracers for metabotropic glutamate receptor binding |
US7452911B2 (en) | 2002-10-31 | 2008-11-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |
DE10250708A1 (de) * | 2002-10-31 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
US7351719B2 (en) | 2002-10-31 | 2008-04-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds |
ITMI20030151A1 (it) * | 2003-01-30 | 2004-07-31 | Recordati Ind Chimica E Farma Ceutica S P A | Uso di antagonisti selettivi del recettore mglu5 per il trattamento di disfunzioni neuromuscolari del tratto urinario inferiore. |
EP2028180A1 (en) * | 2003-03-04 | 2009-02-25 | ADDEX Pharma S.A. | Novel aminopyridine derivatives as mGluR5 antagonists |
RU2333200C2 (ru) | 2003-03-07 | 2008-09-10 | Астеллас Фарма Инк. | Азотсодержащие гетероциклические производные, содержащие 2,6-дизамещенный стирил |
TWI292318B (en) | 2003-03-10 | 2008-01-11 | Hoffmann La Roche | Imidazol-4-yl-ethynyl-pyridine derivatives |
UA80888C2 (en) * | 2003-06-05 | 2007-11-12 | Hoffmann La Roche | Imidazole derivatives as glutmate receptor antagonists |
US7531529B2 (en) | 2003-06-05 | 2009-05-12 | Roche Palo Alto Llc | Imidazole derivatives |
MXPA05013233A (es) * | 2003-06-12 | 2006-03-09 | Hoffmann La Roche | Derivados de imidazol heteroaril-substituidos como antagonistas del receptor de glutamato. |
WO2005007641A1 (en) * | 2003-07-03 | 2005-01-27 | Euro-Celtique S.A. | 2-pyridine alkyne derivatives useful for treating pain |
US7091222B2 (en) * | 2003-07-03 | 2006-08-15 | Hoffmann-La Roche Inc. | Imidazole derivatives |
AR046276A1 (es) | 2003-10-07 | 2005-11-30 | Renovis Inc | Derivados de amida como ligandos de canales ionicos y composiciones farmaceuticas y metodos que los utilizan. |
WO2005044267A1 (en) * | 2003-10-31 | 2005-05-19 | Astrazeneca Ab | Alkynes ii |
JP2007509934A (ja) * | 2003-10-31 | 2007-04-19 | アストラゼネカ アクチボラグ | アルキン類iii |
CA2549967A1 (en) * | 2003-10-31 | 2005-05-19 | Astrazeneca Ab | Alkynes i |
GB0325956D0 (en) * | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
US7592373B2 (en) | 2003-12-23 | 2009-09-22 | Boehringer Ingelheim International Gmbh | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds |
DE102004017934A1 (de) | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
US20050245529A1 (en) * | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim International Gmbh | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |
DE102004017930A1 (de) * | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
US7524862B2 (en) | 2004-04-14 | 2009-04-28 | Boehringer Ingelheim International Gmbh | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |
DE102004017935A1 (de) * | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
JP4690395B2 (ja) | 2004-06-01 | 2011-06-01 | エフ.ホフマン−ラ ロシュ アーゲー | mGlu5レセプターアンタゴニストとしてのピリジン−4−エチニル−イミダゾール及びピラゾール |
NZ552031A (en) * | 2004-06-16 | 2009-06-26 | Wyeth Corp | Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase |
JP2008503460A (ja) * | 2004-06-16 | 2008-02-07 | ワイス | β−セクレターゼのインヒビターとしてのジフェニルイミダゾピリミジンおよびイミダゾールアミン |
GB0413605D0 (en) * | 2004-06-17 | 2004-07-21 | Addex Pharmaceuticals Sa | Novel compounds |
JP2008526966A (ja) | 2005-01-14 | 2008-07-24 | ワイス | β−セクレターゼの阻害のためのアミノ−イミダゾロン |
AU2006205920B2 (en) | 2005-01-14 | 2012-11-15 | F. Hoffmann-La Roche Ag | Thiazole-4-carboxamide derivatives as mGluR5 antagonists |
AU2006211159A1 (en) * | 2005-02-01 | 2006-08-10 | Wyeth | Amino-pyridines as inhibitors of beta-secretase |
BRPI0606902A2 (pt) * | 2005-02-14 | 2009-07-28 | Wyeth Corp | composto; método para o tratamento de uma doença ou distúrbio associado a atividade excessiva de bace em um paciente que dele necessite; método para modular a atividade de bace; composição farmacêutica |
US7576099B2 (en) | 2005-02-28 | 2009-08-18 | Renovis, Inc. | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
BRPI0607583A2 (pt) * | 2005-03-04 | 2009-09-15 | Hoffmann La Roche | derivados de piridin-2-carboxamida como antagonistas mglur5, método para sua preparação, medicamento contendo os mesmos, bem como uso relacionado aos referidos compostos |
GB0508319D0 (en) * | 2005-04-25 | 2005-06-01 | Novartis Ag | Organic compounds |
WO2007005404A1 (en) * | 2005-06-30 | 2007-01-11 | Wyeth | AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR ß-SECRETASE MODULATION |
TW200738683A (en) * | 2005-06-30 | 2007-10-16 | Wyeth Corp | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation |
FR2889187B1 (fr) * | 2005-07-28 | 2007-09-07 | Servier Lab | Nouveaux composes 1,1-pyridinyloxycyclopropanamines polysusbstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR2889188B1 (fr) * | 2005-07-28 | 2007-09-07 | Servier Lab | Nouveaux composes 1,1-pyridinylaminocyclopropanamines polysubstitues, leur procede de preparation et les compositions phamaceutiques qui les contiennent |
TW200730523A (en) * | 2005-07-29 | 2007-08-16 | Wyeth Corp | Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation |
US7531541B2 (en) * | 2005-09-20 | 2009-05-12 | Vanderbilt University | Partial mGluR5 antagonists for treatment of anxiety and CNS disorders |
BRPI0616757A2 (pt) * | 2005-09-26 | 2011-06-28 | Wyeth Corp | composto da fórmula i; processo para o tratamento de uma doença ou de um distúrbio associado com a atividade excessiva de bace; processo para a modulação da atividade de bace; processo para o tratamento da doença de alzheimer; e composição farmacêutica |
GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
CA2634037A1 (en) * | 2005-12-19 | 2007-07-12 | Wyeth | 2-amino-5-piperidinylimidazolone compounds and use thereof for .beta.-secretase modulation |
DE102005062985A1 (de) * | 2005-12-28 | 2007-07-05 | Grünenthal GmbH | Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln |
WO2007100536A1 (en) * | 2006-02-24 | 2007-09-07 | Wyeth | DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE |
NZ570887A (en) | 2006-03-30 | 2011-05-27 | Univ Pennsylvania | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques |
BRPI0710328A2 (pt) * | 2006-05-08 | 2011-08-09 | Ariad Pharma Inc | composto da fórmula i, um tautomer da mesma, ou um sal farmaceuticamente aceitável, hidrato ou outro solvato do mesmo e método para o tratamento de cáncer em um mamìfero necessitado do mesmo e composição |
US7700606B2 (en) * | 2006-08-17 | 2010-04-20 | Wyeth Llc | Imidazole amines as inhibitors of β-secretase |
MX2009003102A (es) * | 2006-09-21 | 2009-04-01 | Wyeth Corp | INDOLILALQUILPIRIDIN-2-AMINAS PARA LA INHIBICION DE ß-SECRETASA. |
CA2670116C (en) | 2006-11-22 | 2015-03-10 | Seaside Therapeutics, Llc | Methods of treating mental retardation, down's syndrome, fragile x syndrome and autism |
AU2007336369B2 (en) | 2006-12-21 | 2013-01-17 | F. Hoffmann-La Roche Ag | Polymorphs of a mGluR5 receptor antagonist |
UA109896C2 (xx) * | 2007-02-22 | 2015-10-26 | Похідні імінопіридину та їх застосування як мікробіоцидів | |
DK2124562T3 (en) | 2007-03-09 | 2016-08-01 | Second Genome Inc | BICYCLOHETEROARYLFORBINDELSER AS P2X7 modulators and uses thereof |
CN101679261A (zh) * | 2007-03-09 | 2010-03-24 | 阿斯利康(瑞典)有限公司 | 哌嗪和哌啶mGluR5增效剂 |
PE20090160A1 (es) * | 2007-03-20 | 2009-02-11 | Wyeth Corp | COMPUESTOS AMINO-5-[4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA |
AR065814A1 (es) * | 2007-03-23 | 2009-07-01 | Wyeth Corp | Derivados de 5-fenilimidazolona,inhibidores de beta-secretasa,composiciones farmaceuticas que los contienen y usos para prevenir y/o tratar trastornos asociados a niveles beta-amiloides elevados. |
US8853392B2 (en) * | 2007-06-03 | 2014-10-07 | Vanderbilt University | Benzamide mGluR5 positive allosteric modulators and methods of making and using same |
WO2008151184A1 (en) * | 2007-06-03 | 2008-12-11 | Vanderbilt University | Benzamide mglur5 positive allosteric modulators and methods of making and using same |
GB0713686D0 (en) | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
US8034806B2 (en) * | 2007-11-02 | 2011-10-11 | Vanderbilt University | Bicyclic mGluR5 positive allosteric modulators and methods of making and using same |
MX2011006680A (es) | 2008-12-24 | 2011-07-12 | Astrazeneca Ab | Compuestos etanaminicos y su uso para tratar la depresion. |
US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
CN102459185B (zh) * | 2009-04-20 | 2015-06-03 | 田边三菱制药株式会社 | 新型甲状腺激素β受体激动剂 |
AR080055A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1 |
WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
JP5748777B2 (ja) | 2010-02-02 | 2015-07-15 | ノバルティス アーゲー | Crf受容体アンタゴニストとしてのシクロヘキシルアミド誘導体 |
WO2011109398A2 (en) | 2010-03-02 | 2011-09-09 | President And Fellows Of Harvard College | Methods and compositions for treatment of angelman syndrome and autism spectrum disorders |
US8420661B2 (en) * | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
US20110294879A1 (en) | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
US20120016021A1 (en) | 2010-07-15 | 2012-01-19 | Xenoport, Inc. | Methods of treating fragile x syndrome, down's syndrome, autism and related disorders |
US8772300B2 (en) * | 2011-04-19 | 2014-07-08 | Hoffmann-La Roche Inc. | Phenyl or pyridinyl-ethynyl derivatives |
US8546416B2 (en) | 2011-05-27 | 2013-10-01 | Novartis Ag | 3-spirocyclic piperidine derivatives as ghrelin receptor agonists |
AU2013255458A1 (en) | 2012-05-03 | 2014-10-09 | Novartis Ag | L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists |
SG11201501375YA (en) * | 2012-10-18 | 2015-03-30 | Hoffmann La Roche | Ethynyl derivatives as modulators of mglur5 receptor activity |
KR101684816B1 (ko) * | 2012-10-18 | 2016-12-20 | 에프. 호프만-라 로슈 아게 | mGluR5 수용체 활성의 조절제로서 에틴일 유도체 |
UA116023C2 (uk) | 2013-07-08 | 2018-01-25 | Ф. Хоффманн-Ля Рош Аг | Етинільні похідні як антагоністи метаботропного глутаматного рецептора |
EP2853565A1 (en) | 2013-09-27 | 2015-04-01 | Consejo Superior De Investigaciones Científicas | Glutamate receptor photomodulators |
CN106146391A (zh) * | 2015-04-15 | 2016-11-23 | 中国科学院上海药物研究所 | 5-芳香炔基取代的苯甲酰胺类化合物及其制备方法、药物组合物和用途 |
EP3411010A1 (fr) * | 2016-02-03 | 2018-12-12 | Galderma Research & Development | Nouveaux composes propynyl bi-aromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations |
US10449186B2 (en) * | 2017-06-21 | 2019-10-22 | University Of Kentucky Research Foundation | Phenylethynyl-substituted benzenes and heterocycles for the treatment of cancer |
WO2019025931A1 (en) | 2017-07-31 | 2019-02-07 | Novartis Ag | USE OF A MUSSEL FOR REDUCING THE USE OF COCAINE OR FOR PREVENTING A RECHUTE IN THE USE OF COCAINE |
CN107400256B (zh) * | 2017-08-14 | 2019-04-19 | 深圳市精研科洁科技股份有限公司 | 一种抗紫外线塑料添加剂的制备方法 |
WO2023122212A2 (en) | 2021-12-21 | 2023-06-29 | Southern Research Institute | Substituted phenyl ethynyl pyridine carboxamides as potent inhibitors of sars virus |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4006240A (en) * | 1975-03-19 | 1977-02-01 | Ho Andrew K S | Alcohol aversion process by enzyme inhibition |
NO174506B (no) * | 1984-10-30 | 1994-02-07 | Usv Pharma Corp | Analogifremgangsmaate ved fremstilling av terapeutisk aktive forbindelser |
EP0334119B1 (en) * | 1988-03-21 | 1993-06-16 | Boehringer Ingelheim Pharmaceuticals Inc. | Compounds for inhibiting the biosynthesis of lipoxygenase-derived metabolites of arachidonic acid |
US5013744B1 (en) * | 1989-12-29 | 1994-09-20 | Allegran Inc | Acetylenes disubstituted with a pyridinyl group and a substituted phenyl group having retinoid like activity |
JPH05500781A (ja) * | 1990-08-08 | 1993-02-18 | ゼネラル・エレクトリック・カンパニイ | 不織フェルトを使った繊維強化熱可塑性合成樹脂の製造方法 |
GB9515412D0 (en) * | 1995-07-27 | 1995-09-27 | Pharmacia Spa | 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives |
JPH11509847A (ja) * | 1995-07-31 | 1999-08-31 | ノボ ノルディスク アクティーゼルスカブ | ヘテロ環式化合物、それらの調製及び使用 |
IT1276153B1 (it) * | 1995-11-17 | 1997-10-27 | Roberto Pellicciari | Derivati di glicina ad attivita' antagonista dei recettori metabotropi del glutammato |
-
1998
- 1998-07-06 TW TW087110887A patent/TW544448B/zh not_active IP Right Cessation
- 1998-07-08 AR ARP980103330A patent/AR016314A1/es unknown
- 1998-07-09 ES ES98941308T patent/ES2308811T3/es not_active Expired - Lifetime
- 1998-07-09 WO PCT/EP1998/004266 patent/WO1999002497A2/en active IP Right Grant
- 1998-07-09 ID IDW20000009A patent/ID23889A/id unknown
- 1998-07-09 DE DE69839398T patent/DE69839398T2/de not_active Expired - Lifetime
- 1998-07-09 AU AU89743/98A patent/AU738973B2/en not_active Ceased
- 1998-07-09 BR BR9811685-1A patent/BR9811685A/pt not_active IP Right Cessation
- 1998-07-09 RU RU2000102667/04A patent/RU2203889C2/ru not_active IP Right Cessation
- 1998-07-09 AT AT98941308T patent/ATE393145T1/de not_active IP Right Cessation
- 1998-07-09 PE PE1998000606A patent/PE97799A1/es not_active Application Discontinuation
- 1998-07-09 PL PL98343865A patent/PL343865A1/xx unknown
- 1998-07-09 NZ NZ502210A patent/NZ502210A/en unknown
- 1998-07-09 CN CNB988070502A patent/CN1203060C/zh not_active Expired - Fee Related
- 1998-07-09 EP EP98941308A patent/EP0998459B1/en not_active Expired - Lifetime
- 1998-07-09 KR KR1020007000271A patent/KR20010021712A/ko not_active Application Discontinuation
- 1998-07-09 IL IL13390498A patent/IL133904A0/xx unknown
- 1998-07-09 CA CA2295678A patent/CA2295678C/en not_active Expired - Fee Related
- 1998-07-09 SK SK23-2000A patent/SK232000A3/sk unknown
- 1998-07-09 JP JP2000502025A patent/JP3481208B2/ja not_active Expired - Fee Related
- 1998-07-09 PT PT98941308T patent/PT998459E/pt unknown
- 1998-07-09 TR TR2000/00059T patent/TR200000059T2/xx unknown
- 1998-07-09 HU HU0004225A patent/HUP0004225A3/hu unknown
- 1998-07-10 MY MYPI98003161A patent/MY119800A/en unknown
-
2000
- 2000-01-10 NO NO20000124A patent/NO20000124L/no not_active Application Discontinuation
- 2000-11-27 US US09/722,803 patent/US6656957B1/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
MOTIN, L., et al.,Effect of P2−purinoceptor antagonists on glutamatergic transmission in the rat hippocampus,Br. J. Pharmacol.,115,pp.1276−1280 (1995) |
Also Published As
Publication number | Publication date |
---|---|
BR9811685A (pt) | 2000-09-19 |
CN1262676A (zh) | 2000-08-09 |
DE69839398D1 (de) | 2008-06-05 |
PT998459E (pt) | 2008-07-31 |
TR200000059T2 (tr) | 2000-06-21 |
CA2295678A1 (en) | 1999-01-21 |
KR20010021712A (ko) | 2001-03-15 |
CN1203060C (zh) | 2005-05-25 |
ES2308811T3 (es) | 2008-12-01 |
IL133904A0 (en) | 2001-04-30 |
NO20000124L (no) | 2000-03-02 |
PE97799A1 (es) | 1999-11-08 |
DE69839398T2 (de) | 2009-05-28 |
JP2001509504A (ja) | 2001-07-24 |
WO1999002497A2 (en) | 1999-01-21 |
CA2295678C (en) | 2010-04-13 |
HUP0004225A2 (hu) | 2001-05-28 |
WO1999002497A3 (en) | 1999-04-01 |
HUP0004225A3 (en) | 2001-06-28 |
SK232000A3 (en) | 2000-06-12 |
EP0998459B1 (en) | 2008-04-23 |
ATE393145T1 (de) | 2008-05-15 |
US6656957B1 (en) | 2003-12-02 |
NO20000124D0 (no) | 2000-01-10 |
EP0998459A2 (en) | 2000-05-10 |
AR016314A1 (es) | 2001-07-04 |
RU2203889C2 (ru) | 2003-05-10 |
PL343865A1 (en) | 2001-09-10 |
NZ502210A (en) | 2002-07-26 |
AU8974398A (en) | 1999-02-08 |
TW544448B (en) | 2003-08-01 |
ID23889A (id) | 2000-05-25 |
MY119800A (en) | 2005-07-29 |
AU738973B2 (en) | 2001-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3481208B2 (ja) | ピリジン誘導体 | |
EP0733033B1 (en) | Pharmaceutically active substituted aromatic compounds | |
US5151423A (en) | Heterocyclic n-oxide derivatives of substituted benzo[5,6]cycloheptapyridines, compositions and methods of use | |
US5723460A (en) | Cyclo (alkyl and alkenyl) phenyl-alkenylyl heteroaryl compounds and pharmaceutical compositions containing same | |
US7989457B2 (en) | Glucagon receptor antagonists, preparation and therapeutic uses | |
JP2002537383A (ja) | Pdeiv阻害化合物、組成物および治療方法 | |
US8415380B2 (en) | Pyridine and pyrimidine derivatives as MGLUR2 antagonists | |
TWI292318B (en) | Imidazol-4-yl-ethynyl-pyridine derivatives | |
CZ203494A3 (en) | Tri-substituted phenyl derivatives, process of their preparation and pharmaceutical preparations in which they are comprised | |
CN105073729A (zh) | RORγt的苯基连接的喹啉基调节剂 | |
JPH10508587A (ja) | ロイコトリエン生合成阻害剤としてのビスアリールカルビノールケイ皮酸 | |
US5602153A (en) | Method of using 1-arylheteroarylalkyl substituted-1H-1,2,4-triazole compounds for treatment of a giaucoma disorder | |
JP2002543064A (ja) | Pde4インヒビターとなるヘテロ置換ピリジン誘導体 | |
JPH02275858A (ja) | ピリジン化合物 | |
CN101119974A (zh) | 作为ppar活化剂的酰胺衍生物 | |
EP0094422B1 (en) | Substituted pyridines | |
CZ200068A3 (cs) | Deriváty pyridinu a farmaceutický prostředek, který je obsahuje | |
MXPA00000433A (en) | Pyridine derivatives | |
JP2007508267A (ja) | 複素環式化合物 | |
JP2007509039A (ja) | シクロペンテン化合物 | |
JP2007508266A (ja) | シクロヘキセン化合物 | |
TW200305567A (en) | Compounds and use thereof for decreasing activity of hormonesensitive lipase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071010 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081010 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091010 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091010 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101010 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111010 Year of fee payment: 8 |
|
LAPS | Cancellation because of no payment of annual fees |